Dr David Moore PhD

 

Senior Lecturer

Public Health, Epidemiology and Biostatistics

Contact details

Telephone +44 (0)121 414 7449

Fax +44 (0)121 414 7878

Email d.j.moore@bham.ac.uk

Public Health, Epidemiology and Biostatistics
School of Health and Population Sciences
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham, B15 2TT

About

Dr Moore is responsible for..

  • leading teams undertaking systematic reviews and project managing the production of systematic reviews
  • appraising the strengths and weaknesses of systematic reviews undertaken by other reviewers
  • improving the incorporation of research evidence in population level health care decisions
  • teaching at both undergraduate and postgraduate level and academic tutor to post graduate students

Biography

David also has a background in primary research in ophthalmology through which he obtained a PhD. He has previously worked at the Institute of Ophthalmology (London), the United Medical and Dental Schools of Guy's and St. Thomas' Hospitals and the University of Auckland, New Zealan

Teaching

Teaching Programmes

Research

  • Health Technology Assessment
  • Systematic Reviews
  • Evidence Synthesis.

Publications

Connock M; Hyde C, Moore D. Cautions regarding the fitting and interpretation of survival curves: examples from NICE Single Technology Appraisals of drugs for cancer. PharmacoEconomics: 2011; 29(10):827-837

Malottki K, Barton P, Tsourapas A, Uthman A, Liu Z, Routh R, Connock R, Jobanputra P, Moore D, Fry-Smith A, Chen Y. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation. Health Technology Assessment: 2011; 15(14)

Connock M, Tubeuf S,  Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technology Assessment: 2010; Vol. 14 Suppl. 2; 1-10

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technology Assessment 2010; Vol. 14: Suppl. 1; 17-21

Meads C, Round J, Tubeuf S, Moore D, Pennant M, Bayliss S. Cetuximab for the first-line treatment of metastatic colorectal cancer Health Technology Assessment 2010;14: Suppl.1; 1-8

Chen Y-F, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JSR, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technology Assessment 2009; 13(49)

Moore D, Adi Y, Connock M, Bayliss S. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocrine Disorders 2009, 9:20 doi:10.1186/1472-6823-9-20

Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024

Back to top